FDA clears anticlotting drug Eliquis

December 28, 2012

The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes and heart attacks.

The agency previously rejected the drug twice, most recently in June, awaiting additional data from company trials.

The FDA cleared the pill for treating the most common type of irregular heartbeat—atrial fibrillation—in patients at risk for strokes or dangerous clots.

About a quarter of all people aged 40 and older develop atrial fibrillation, a condition in which the heart's two upper chambers contract irregularly and don't pump blood efficiently.

Bristol-Myers Squibb shares rose 60 cents, or 2 percent, to $32.50 in after-hours trading.

Explore further: Bristol-Myers, Pfizer's Eliquis approved in Japan

shares

Related Stories

Bristol-Myers, Pfizer's Eliquis approved in Japan

December 26, 2012
Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Bristol-Pfizer anticlot drug gets key EU approval

November 20, 2012
European regulators have approved a crucial new anticlotting drug, Eliquis, for preventing strokes and dangerous clots in the circulatory system.

Anti-clot drug recommended for new approval in EU

September 21, 2012
(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

FDA cites higher death risk in Sanofi drug study

July 22, 2011
(AP) -- Federal health regulators are warning doctors that a heart drug from Sanofi was associated with fatal heart problems in a recently halted company study.

FDA adds new heart warning to Sanofi's Multaq

December 19, 2011
Federal health officials have added new safety warnings to the heart rhythm drug Multaq after company studies linked the pill to higher rates of heart attack, stroke and death in a subset of patients.

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.